Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TBX6 CRISPR/Cas9 KO Plasmid (h): sc-405632
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TBX6 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the TBX6 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TBX6 Antibody (1D11): sc-517027
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TBX6 CRISPR/Cas9 KO Plasmid (h) | sc-405632 | 20 µg | $397.00 |
Overview
TBX6 encodes a T-box family transcription factor that regulates mesoderm specification and paraxial mesoderm patterning during early human development, coordinating gene programs that drive somite formation and vertebral segmentation. It functions within transcriptional networks that integrate developmental signaling inputs, including Notch and WNT/β-catenin pathways, to control lineage commitment and axial organization. Altered TBX6 dosage or function has been linked to congenital spine and rib malformations, making it a useful node for studying the genetic architecture of vertebral development. In cellular models, TBX6 perturbation is commonly used to interrogate differentiation trajectories, enhancer logic, and transcription factor–driven fate decisions.
TBX6 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TBX6 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the TBX6 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the TBX6 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish TBX6 protein expression.
This CRISPR knockout system enables efficient generation of TBX6-deficient cell models for investigation of TBX6 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting TBX6 exon(s) critical for TBX6 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple TBX6 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by TBX6 CRISPR/Cas9 KO Plasmid (h) and TBX6 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the TBX6 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by TBX6 HDR Plasmid (h) and TBX6 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by TBX6 homology arms to support homology-directed repair at defined TBX6 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.